ALK Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature

Activating mutations and fusions of the ALK oncogene have been identified as drivers in a number malignancies. Crizotinib subsequent tyrosine kinase inhibitors improved treatment outcomes for these patients. In this paper, we discuss case an adolescent patient with acute myeloid leukemia, who was to activating fusion, which is rare finding has never reported cases AML without monosomy 7. added patient’s frontline therapy well tolerated. more common gene alterations, existing data supports use targeted agents post-HSCT maintenance therapy; however, crizotinib not able be used due inability obtain insurance coverage.